Multi-Omics Approaches to Define Calcific Aortic Valve Disease Pathogenesis

• Published in: Circulation research 2021-04, Vol.128 (9), p.1371-1397
• Main Authors: Blaser, Mark C., Kraler, Simon, Lüscher, Thomas F., Aikawa, Elena
• Format: Article
• Language: English
• Subjects: Aortic Valve - pathology; Aortic Valve - physiology; Aortic Valve - physiopathology; Aortic Valve - surgery; Aortic Valve Stenosis - etiology; Aortic Valve Stenosis - genetics; Aortic Valve Stenosis - physiopathology; Aortic Valve Stenosis - surgery; Biomechanical Phenomena - physiology; Calcinosis - etiology; Calcinosis - genetics; Calcinosis - physiopathology; Calcinosis - surgery; Computational Biology - methods; Disease Progression; Drug Discovery; Epigenesis, Genetic; Gene Expression; Genomics; Heart Failure - etiology; Humans; Mass Spectrometry; Medical Illustration; Metabolomics; Phenotype; Proteomics; Transcatheter Aortic Valve Replacement; Transcriptome
• ISSN: 0009-7330; 1524-4571; 1524-4571
• DOI: 10.1161/CIRCRESAHA.120.317979

Calcific aortic valve disease sits at the confluence of multiple world-wide epidemics of aging, obesity, diabetes, and renal dysfunction, and its prevalence is expected to nearly triple over the next 3 decades. This is of particularly dire clinical relevance, as calcific aortic valve disease can progress rapidly to aortic stenosis, heart failure, and eventually premature death. Unlike in atherosclerosis, and despite the heavy clinical toll, to date, no pharmacotherapy has proven effective to halt calcific aortic valve disease progression, with invasive and costly aortic valve replacement representing the only treatment option currently available. This substantial gap in care is largely because of our still-limited understanding of both normal aortic valve biology and the key regulatory mechanisms that drive disease initiation and progression. Drug discovery is further hampered by the inherent intricacy of the valvular microenvironmenta unique anatomic structure, a complex mixture of dynamic biomechanical forces, and diverse and multipotent cell populations collectively contributing to this currently intractable problem. One promising and rapidly evolving tactic is the application of multiomics approaches to fully define disease pathogenesis. Herein, we summarize the application of (epi)genomics, transcriptomics, proteomics, and metabolomics to the study of valvular heart disease. We also discuss recent forays toward the omics-based characterization of valvular (patho)biology at single-cell resolution; these efforts promise to shed new light on cellular heterogeneity in healthy and diseased valvular tissues and represent the potential to efficaciously target and treat key cell subpopulations. Last, we discuss systems biology- and network medicine-based strategies to extract meaning, mechanisms, and prioritized drug targets from multiomics datasets.